NASDAQ: GERNGeron Corp Stock
$1.44+0.00 (+0%)
Updated Jul 21, 2026
GERN Price
$1.44
Fair Value Price
N/A
Market Cap
$923.79M
52 Week Low
$1.04
52 Week High
$2.01
P/E
-13.09x
P/B
4.03x
P/S
5.09x
PEG
N/A
Dividend Yield
N/A
Revenue
$196.12M
Earnings
-$67.31M
Gross Margin
97.3%
Operating Margin
-18.21%
Profit Margin
-34.3%
Debt to Equity
1.33
Operating Cash Flow
-$126M
Beta
1.26
Next Earnings
Aug 5, 2026
Ex-Dividend
N/A
Next Dividend
N/A
GERN Overview
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine GERN's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
GERN
Ranked#89 of 464
Ranked#89 of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $254.22 | A | |
| $11.20 | A | |
| $8.78 | A |
Be the first to know about important GERN news, forecast changes, insider trades & much more!
GERN News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how GERN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GERN is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
GERN is good value based on its book value relative to its share price (4.03x), compared to the US Biotechnology industry average (5.42x)
P/B vs Industry Valuation
GERN is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more GERN due diligence checks available for Premium users.
Valuation
GERN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-13.09x
Industry
21.35x
Market
12.07x
GERN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.03x
Industry
5.42x
GERN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
GERN's financial health
Profit margin
Revenue
$51.8M
Net Income
-$3.6M
Profit Margin
-7%
GERN's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
GERN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$534.1M
Liabilities
$305.0M
Debt to equity
1.33
GERN's short-term assets ($498.53M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GERN's short-term assets ($498.53M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GERN's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
GERN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$62.9M
Investing
$51.9M
Financing
$2.4M
GERN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
GERN vs Biotech Stocks
Geron Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.